Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 4, 2014, Pages 828-833

  Dilling, Thomas J ^a   Extermann, Martine ^a   Kim, Jongphil ^a   Thompson, Lora M ^a   Yue, Binglin ^a   Stevens, Craig W ^a   Antonia, Scott ^a   Gray, Jhanelle ^a   Williams, Charles ^a   Haura, Eric ^a   Pinder Schenck, Mary ^a   Tanvetyanon, Tawee ^a   Kim, Sungjune ^a   Chiappori, Alberto ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DIAGNOSIS; DISEASES; DRUG PRODUCTS; ELECTROPHYSIOLOGY; OXYGEN REDUCTION REACTION; REGRESSION ANALYSIS; TOXICITY;

CONCURRENT CHEMORADIATION; EASTERN COOPERATIVE ONCOLOGY GROUP; INSTITUTIONAL REVIEW BOARDS; LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCERS; METHODS AND MATERIALS; PROGRESSION FREE SURVIVAL; PULMONARY COMPLICATIONS; RECURSIVE PARTITIONING ANALYSIS;

RADIOTHERAPY;

CETUXIMAB; DOCETAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; LUNG DISEASE; MACULOPAPULAR RASH; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT RESPONSE; WEIGHT REDUCTION; ADENOCARCINOMA; BREATHING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MOVEMENT (PHYSIOLOGY); PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOVEMENT; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESPIRATION; TAXOIDS;

EID: 84908220177     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.07.023     Document Type: Article

References (33)

1. R.O. Dillman, J. Herndon, and S.L. Seagren Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
2. R. Komaki, C.B. Scott, and W.T. Sause Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group Int J Radiat Oncol Biol Phys 39 1997 537 544
3. D.H. Lau, J.J. Crowley, and D.R. Gandara Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer J Clin Oncol 16 1998 3078 3081
4. M. Werner-Wasik, C. Scott, and J.D. Cox Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival Int J Radiat Oncol Biol Phys 48 2000 1475 1482
5. D.W. Bruner, B. Movsas, and A. Konski Outcomes research in cancer clinical trial cooperative groups: The RTOG model Qual Life Res 13 2004 1025 1041
6. K. Furuse, M. Fukuoka, and M. Kawahara Phase III study of concurrent versus sequential thoracic radiation therapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2699
7. P. Fournel Randomized phase III trial of sequential chemoradiation therapy compared with concurrent chemoradiation therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 23 2005 5910 5917
8. R.M. Huber Simultaneous chemoradiation therapy compared with radiation therapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group J Clin Oncol 24 2006 4397 4404
9. W.J. Curran, R. Paulus, and C.J. Langer Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410 JNCI J Natl Cancer Inst 103 2011 1452 1460
10. D.F. Cella, A.E. Bonomi, and S.R. Lloyd Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument Lung Cancer 12 1995 199 220
11. D.M. Hann, P.B. Jacobsen, and L.M. Azzarello Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory Qual Life Res 7 1998 301 310
12. S. Katz, A.B. Ford, and R.W. Moskowitz Studies of illness in the aged. The Index of ADL: A standardized measure of biological and psychosocial function JAMA 185 1963 914 919
13. M.P. Lawton, and E.M. Brody Assessment of older people. Self-maintaining and instrumental activities of daily living Gerontology 9 1969 179 186
14. M.P. Lawton, M. Moss, and M. Fulcomer A research and service oriented multilevel assessment instrument J Gerontol 37 1982 91 99
15. M.P. Lawton Scales to measure competence in everyday activities Psychopharmacol Bull 24 1988 609 614
16. B.S. Linn, M.W. Linn, and L. Gurel Cumulative illness rating scale J Am Geriatr Soc 16 1968 622 626
17. Miller M, Towers A. A manual of guidelines of scoring the cumulative illness rating scale for geriatrics (CIRS-G). Psychiatry Res, 41,237-48, 1992.
18. M. Extermann, J. Overcash, and G.H. Lyman Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582 1587
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
20. S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174
21. L. Milas, K. Mason, and N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708
22. M. Thomas Cetuximab: Adverse event profile and recommendations for toxicity management Clin J Oncol Nurs 9 2005 332 338
23. J.A. Bonner, P.M. Harari, and J. Giralt Radiation therapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
24. D.R. Gandara, K. Chansky, and K.S. Albain Consolidation docetaxel after concurrent chemoradiation therapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
25. K. Kelly, L. Gaspar, and K. Chansky Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiation therapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer Proc Am Soc Clin Oncol 23 2005 634s (Abst 758)
26. G. Bepler, C. Williams, and A. Chiappori Docetaxel and gefitinib in the first line treatment of elderly patients (≥ 70 years) with advanced non-small cell lung cancer (ANSCLC): Results of a phase II trial Proc Am Soc Clin Oncol 23 2005 658s (Abst # 7155)
27. E.S. Kim, A.M. Mauer, and H.T. Tran A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final Report Proc Am Soc Clin Oncol 22 2003 642 (Abst 2581)
28. M. Mizumoto, H. Harada, and H. Asakura Frequency and characteristics of docetaxel-induced radiation recall phenomenon Int J Radiat Oncol Biol Phys 66 2006 1187 1191
29. N. Hanna, M. Neubauer, and C. Yiannoutsos Phase III Study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
30. R.B. Barriger, A.J. Fakiris, and N. Hanna Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel Int J Radiat Oncol Biol Phys 78 2010 1381 1386
31. S.I. Jalal, H.D. Riggs, and A. Melnyk Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: Analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Ann Oncol 23 2011 1730 1738
32. J.D. Bradley, R. Paulus, and R. Komaki A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiation therapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617 J Clin Oncol 2013 31 (Abstr 7501)
33. J.D. Bradley, C.B. Scott, and K.J. Paris A phase III comparison of radiation therapy with or without recombinant β-interferon for poor-risk patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 52 2002 1173 1179